Lynn Bodarky Joins HiFiBiO Therapeutics as SVP, Global Head of Business Development and Alliance Management

CAMBRIDGE, Mass. – May 9th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced the appointment of Lynn Bodarky as a Senior Vice President to oversee the company’s business development and alliance management activities, reporting directly to HiFiBiO’s President and CEO, Dr. Liang Schweizer.

“We are very excited to bring on board an experienced top business leader of Lynn’s caliber,” said Liang Schweizer. “In less than 5 years, we have discovered 8 clinical candidates with 3 IND filings centered around immune modulation, including HFB200301, our first-in-class anti-TNFR2 agonist and HFB301001, our differentiated OX40 agonist programs, both of which are currently in Phase I clinical trials. It is great to have Lynn join us at this pivotal stage of the company, as we continue to progress our rich pipeline as well as strengthen our unique single-cell driven Drug Intelligent Science (DIS®) approach. Lynn will be an integral part of the executive leadership team at HiFiBiO Therapeutics, leading our efforts for pipeline and platform collaboration opportunities.”

Ms. Bodarky brings extensive experience in structuring pharma, biotech and academic partnerships and has held multiple senior leadership roles in both small biotech and large multi-national pharmaceutical companies. She has closed deals valued at over $5 billion across therapeutic areas, such as oncology, auto-immune diseases as well as infectious and neurological disorders. Prior to joining HiFiBiO Therapeutics, Ms. Bodarky served as the Vice President of Business Development at Geron Corporation, a company focused on treatments for hematologic malignancies. Previous experiences include senior corporate strategy and business development roles within organizations including Pfizer and Merck & Co., Inc.

“I was attracted to HiFiBiO’s industry leading single-cell DIS® technology and the speed with which the company has developed such a robust pipeline,” said Lynn. “I am thrilled to be joining an organization with such a strong commitment, dynamic team, and shared passion for accelerating therapies to improve outcomes for patients.”

Ms. Bodarky holds an MBA in finance and international business from the Columbia Business School and a BS in accounting from the University of Pennsylvania, Wharton School of Business.

About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical stage biotech company advancing a robust pipeline targeting both the innate and adaptive immunity to treat cancer and autoimmune disease. Our proprietary and versatile DIS® single-cell platform enables the rapid discovery of novel antibody therapeutics with predictive biomarkers through our internal development programs and strategic collaborations. Our passionate team across three continents embraces a fast-paced and engaging work environment to bring transformative medicines to patients.

HiFiBiO® and DIS® are trademarks of HiFiBiO and its affiliates.